517 related articles for article (PubMed ID: 10811379)
1. Treatment of idiopathic restless legs syndrome (RLS) with the D2-agonist cabergoline--an open clinical trial.
Stiasny K; Röbbecke J; Schüler P; Oertel WH
Sleep; 2000 May; 23(3):349-54. PubMed ID: 10811379
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR).
Oertel WH; Benes H; Bodenschatz R; Peglau I; Warmuth R; Happe S; Geisler P; Cassel W; Leroux M; Kohnen R; Stiasny-Kolster K
Neurology; 2006 Sep; 67(6):1040-6. PubMed ID: 16931508
[TBL] [Abstract][Full Text] [Related]
3. A dose-ranging study of pramipexole for the symptomatic treatment of restless legs syndrome: polysomnographic evaluation of periodic leg movements and sleep disturbance.
Jama L; Hirvonen K; Partinen M; Alakuijala A; Hublin C; Tamminen I; Koester J; Reess J
Sleep Med; 2009 Jun; 10(6):630-6. PubMed ID: 19171500
[TBL] [Abstract][Full Text] [Related]
4. Low-dose pramipexole in the management of restless legs syndrome. An open label trial.
Stiasny-Kolster K; Oertel WH
Neuropsychobiology; 2004; 50(1):65-70. PubMed ID: 15179023
[TBL] [Abstract][Full Text] [Related]
5. Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial.
Trenkwalder C; Benes H; Grote L; Happe S; Högl B; Mathis J; Saletu-Zyhlarz GM; Kohnen R;
Mov Disord; 2007 Apr; 22(5):696-703. PubMed ID: 17274039
[TBL] [Abstract][Full Text] [Related]
6. Cabergoline is an effective single-drug treatment for restless legs syndrome: clinical and actigraphic evaluation.
Zucconi M; Oldani A; Castronovo C; Ferini-Strambi L
Sleep; 2003 Nov; 26(7):815-8. PubMed ID: 14655913
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial.
Benes H; Heinrich CR; Ueberall MA; Kohnen R
Sleep; 2004 Jun; 27(4):674-82. PubMed ID: 15283002
[TBL] [Abstract][Full Text] [Related]
8. Influence of cabergoline on motor excitability in patients with restless legs syndrome.
Gorsler A; Liepert J
J Clin Neurophysiol; 2007 Dec; 24(6):456-60. PubMed ID: 18090527
[TBL] [Abstract][Full Text] [Related]
9. Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies.
Fulda S; Wetter TC
Brain; 2008 Apr; 131(Pt 4):902-17. PubMed ID: 17932100
[TBL] [Abstract][Full Text] [Related]
10. Effective cabergoline treatment in idiopathic restless legs syndrome.
Stiasny-Kolster K; Benes H; Peglau I; Hornyak M; Holinka B; Wessel K; Emser W; Leroux M; Kohnen R; Oertel WH
Neurology; 2004 Dec; 63(12):2272-9. PubMed ID: 15623686
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Parkinson's disease and restless legs syndrome with cabergoline, a long-acting dopamine agonist.
Porter MC; Appiah-Kubf LS; Chaudhuri KR
Int J Clin Pract; 2002; 56(6):468-74. PubMed ID: 12166546
[TBL] [Abstract][Full Text] [Related]
12. Restless legs syndrome: clinical experience with long-term treatment.
Clavadetscher SC; Gugger M; Bassetti CL
Sleep Med; 2004 Sep; 5(5):495-500. PubMed ID: 15341896
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome.
Bliwise DL; Freeman A; Ingram CD; Rye DB; Chakravorty S; Watts RL
Sleep Med; 2005 Mar; 6(2):141-7. PubMed ID: 15716217
[TBL] [Abstract][Full Text] [Related]
14. Ropinirole in patients with restless legs syndrome and baseline IRLS total scores ≥ 24: efficacy and tolerability in a 26-week, double-blind, parallel-group, placebo-controlled study followed by a 40-week open-label extension.
Giorgi L; Asgharian A; Hunter B
Clin Ther; 2013 Sep; 35(9):1321-36. PubMed ID: 23938061
[TBL] [Abstract][Full Text] [Related]
15. Dopamine agonists for restless legs syndrome.
Scholz H; Trenkwalder C; Kohnen R; Riemann D; Kriston L; Hornyak M
Cochrane Database Syst Rev; 2011 Mar; 2011(3):CD006009. PubMed ID: 21412893
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of pramipexole in Japanese patients with primary restless legs syndrome: A polysomnographic randomized, double-blind, placebo-controlled study.
Inoue Y; Hirata K; Kuroda K; Fujita M; Shimizu T; Emura N; Uchimura N; Kagimura T; Sha K; Nozawa T
Sleep Med; 2010 Jan; 11(1):11-6. PubMed ID: 19962941
[TBL] [Abstract][Full Text] [Related]
17. Acute placebo-controlled sleep laboratory studies and clinical follow-up with pramipexole in restless legs syndrome.
Saletu M; Anderer P; Saletu-Zyhlarz G; Hauer C; Saletu B
Eur Arch Psychiatry Clin Neurosci; 2002 Aug; 252(4):185-94. PubMed ID: 12242580
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study--the PRELUDE study.
Partinen M; Hirvonen K; Jama L; Alakuijala A; Hublin C; Tamminen I; Koester J; Reess J
Sleep Med; 2006 Aug; 7(5):407-17. PubMed ID: 16815748
[TBL] [Abstract][Full Text] [Related]
19. Polysomnographic sleep measures in patients with uremic and idiopathic restless legs syndrome.
Wetter TC; Stiasny K; Kohnen R; Oertel WH; Trenkwalder C
Mov Disord; 1998 Sep; 13(5):820-4. PubMed ID: 9756152
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of ropinirole in patients with restless legs syndrome and a baseline IRLS total score > or = 24 points--data from the ropinirole clinical trial programme.
Giorgi L; Ritchie SY; Kirsch JM
Curr Med Res Opin; 2006 Oct; 22(10):1867-77. PubMed ID: 17022844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]